Digest Network Come funziona
Network
/
Società
Sc
Non verificato

Scribe Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaIndustriaSalute

3 comunicati stampa

Guarda tutti i comunicati
30/04/2026
Eventi
Salute
Biotecnologia
Scienza
Farmaceutica
Cardiologia
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/02/2026
Industria
Salute
Biotecnologia
Farmaceutica
Cardiologia
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/01/2026
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
Fonte
Scribe Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0